Ocular and orbital complications following radiation therapy of paranasal sinus malignancies and review of literature.
During the period from March 1963 through March 1978, 30 patients with malignant neoplasms of the paranasal sinuses were treated with supervoltage technique at the University of Rochester Medical Center. Twenty-one patients had at least the medial portion of the orbit within the effective treatment volume and the rest of the patients had whole eye irradiation. In paranasal sinus malignancies, orbital involvement with ocular symptoms and signs is quite common; in many patients it can be the presenting problem. Enucleation is necessary in patients with gross orbital tumor. Eye preservation is worthwhile in patients with minimal orbital tumor. Anterior complications are a minimal risk if the technique is good. Posterior complications occur in almost all patients, but are rarely clinically significant until doses of 6000 rad or above are reached. In patients without gross orbital involvement, preservation of the eye can be considered optional treatment. It includes shielding of the anterior structures, but it is usually not possible to protect medial and posterior portions of the eye and orbit. In advanced cases, it is worthwhile to preserve the eye as cure rate is low and posterior eye complications are often late. Because the aim of treatment is cure, dose should not be compromised to prevent complications. Radiation injury to the optic nerve and retina is the major factor in visual loss, but it can be prevented by limiting the retinal and optic nerve dose to less than 6000 rad.
D000368:Aged; D002386:Cataract / Q000209:etiology; D003229:Conjunctival Diseases / Q000209:etiology; D003316:Corneal Diseases / Q000209:etiology; D005128:Eye Diseases / Q000209:etiology*; D005141:Eyelid Diseases / Q000209:etiology; D006801:Humans; D007766:Lacrimal Apparatus Diseases / Q000209:etiology; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009916:Orbital Diseases / Q000209:etiology; D010255:Paranasal Sinus Neoplasms / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000209:etiology* / Q000517:prevention & control; D011878:Radiotherapy / Q000009:adverse effects*; D012164:Retinal Diseases / Q000209:etiology